Azithromycin IV Dosage
For adults with community-acquired pneumonia, administer 500 mg IV once daily for at least 2 days, followed by oral azithromycin 500 mg daily to complete 7-10 days of therapy. 1
Adult Dosing
Community-Acquired Pneumonia
- Loading phase: 500 mg IV once daily for minimum 2 days
- Maintenance phase: Switch to oral 500 mg once daily when clinically appropriate
- Total duration: 7-10 days 1
Pelvic Inflammatory Disease
- IV phase: 500 mg IV once daily for 1-2 days
- Oral phase: 250 mg once daily to complete 7 days
- Note: Add anaerobic coverage if anaerobes suspected 1
Infusion Parameters
- Concentration options:
- 1 mg/mL infused over 3 hours, OR
- 2 mg/mL infused over 1 hour
- Never administer as bolus or IM injection 1
The FDA label explicitly states these are the only acceptable infusion rates, as higher concentrations (4-5 mg/mL) cause significant infusion site reactions including tenderness and erythema 2.
Pediatric Dosing
For children with atypical pneumonia (Mycoplasma, Chlamydia), give 10 mg/kg IV once daily on days 1 and 2, then transition to oral therapy as soon as possible. 3
Specific Pediatric Regimen
- IV loading: 10 mg/kg once daily for 2 days (maximum 500 mg)
- Oral continuation: 5 mg/kg once daily on days 2-5 3
- Do not exceed adult doses 3
Research supports that 10 mg/kg IV dosing (maximum 500 mg) produces comparable pharmacokinetics across pediatric ages 0.5-16 years, with mean AUC₀₋₇₂ of 8.2 mcg·h/mL and Cmax of 2.4 mcg/mL 4. More recent population pharmacokinetic modeling suggests a loading dose of 15 mg/kg followed by 10 mg/kg maintenance doses may optimize target attainment, though this exceeds current guideline recommendations 5.
Dose Adjustments
Renal Impairment
- No adjustment needed for GFR 10-80 mL/min
- Caution advised for GFR <10 mL/min (35% increase in AUC)
- The drug is minimally renally eliminated (11-14% unchanged in urine) 1, 6
Hepatic Impairment
- No specific recommendations available - pharmacokinetics not established in hepatic dysfunction
- Clinical judgment required 1
- Pediatric data suggests 15% dose reduction if ALT >40 U/L 5
Age and Gender
- No adjustments needed 1
Key Clinical Considerations
Pharmacokinetic Profile
- Terminal half-life: 68 hours (adults), 65 hours (pediatrics) 1, 4
- Clearance: 630 mL/min (adults), 10 mL/min/kg 1, 7
- Volume of distribution: 33.3 L/kg - extensive tissue uptake 1, 7
- Protein binding: Variable, 51% at low concentrations to 7% at therapeutic levels 1
The prolonged half-life results from extensive tissue uptake and slow release rather than impaired clearance 7. This explains why plasma concentrations remain quantifiable for 10+ days after single doses.
Transition to Oral Therapy
Switch from IV to oral based on clinical response at physician discretion 1. The guidelines emphasize early transition when possible to minimize IV exposure 3. Oral bioavailability produces approximately 38% of IV Cmax and 52% of IV AUC, but tissue concentrations remain therapeutic 1.
Common Pitfalls
- Never use concentrations >2 mg/mL - significantly increases infusion site reactions 2
- Avoid bolus administration - not studied and potentially dangerous 1
- Do not co-infuse with other medications through same IV line 1
- Stability limits: Diluted solutions stable 24 hours at room temperature or 7 days refrigerated 1
Antimicrobial Stewardship
The guidelines strongly recommend limiting antibiotic exposure and spectrum whenever possible to minimize resistance development 3. Use the shortest effective duration and transition to oral therapy promptly when clinically appropriate.